Clinical trials: Cytomegalovirus
Cytomegalovirus Infection
Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults
This clinical study will assess the safety and immunogenicity of 3 dose levels of mRNA-1647 cytomegalovirus vaccine in CMV-seronegative and CMV-seropositive healthy adults 18-40 years of age.
- Trial name
- NCT04232280
- Testing
- mRNA-1647
- Where
- 9 sites in United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Cytomegalovirus Retinitis, HIV Infections
A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes
To determine a clinically safe and effective dose of intravitreally injected ISIS 2922 and to compare the safety and efficacy of immediate versus delayed treatment in AIDS patients with previously untreated, peripheral…
- Trial name
- NCT00002355
- Testing
- Fomivirsen sodium
- Where
- 13 sites in United States
- Volunteers
- 60 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Cytomegalovirus Retinitis, HIV Infections
A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS
To evaluate the safety and tolerance of long-term ganciclovir (DHPG) therapy for newly diagnosed macular threatening Cytomegalovirus (CMV) retinitis in AIDS patients.
- Trial name
- NCT00002034
- Testing
- Zidovudine, Ganciclovir
- Where
- 9 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Hoffmann-La Roche
CMV Infection
Study Evaluating the Efficacy and Safety of Artesunate
This study is a randomized, open-label, active comparator-controlled, dose-ranging trial of the efficacy and safety of IV artesunate in combination with IV GCV or oral VGCV and SOC treatment compared to GCV or VGCV monotherapy…
- Trial name
- NCT06853184
- Testing
- Artesunate, Ganciclovir (GCV)
- Where
- 4 sites in United States, Australia
- Volunteers
- 90 people
- Sponsor
- Amivas Inc.
Cytomegalovirus (CMV)
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
The main aim of this study is to find out the safety, tolerability and pharmacokinetics (PK) of maribavir for the treatment of CMV infection in children and teenagers after HSCT or SOT and to identify the optimal dose of…
- Trial name
- NCT05319353
- Testing
- Maribavir
- Where
- 53 sites in United States, Australia and 9 more
- Volunteers
- 80 people
- Sponsor
- Takeda
Congenital Cytomegalovirus Infection
Prevention of Maternal-fetal Cytomegalovirus Transmission After Primary Maternal Infection, GW ≤ 14 (PreCyssion)
A phase 3, open-label, single-arm, prospective, multi-center trial of Cytotect CP Biotest (BT097) for prevention of maternal-fetal CMV transmission after primary maternal CMV infection.
- Trial name
- PreCyssion (NCT05170269)
- Testing
- BT097
- Where
- 5 sites in Germany
- Volunteers
- 48 people
- Sponsor
- Biotest
Cytomegalovirus Infection
A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)
The purpose of this study is to evaluate the efficacy and safety of a once-a-day oral or intravenous (IV) dose of Letermovir (MK-8228) in Chinese adult hematopoietic stem cell transplant (HSCT) recipients for the prevention of…
- Trial name
- NCT05763823
- Testing
- Letermovir
- Where
- 21 sites in China
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Cytomegalovirus
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age
The main purpose of study is to evaluate the safety and immunogenicity of different dose levels of mRNA-1647 versus control in healthy cytomegalovirus (CMV)-seronegative and CMV-seropositive female and male participants 9 to 15…
- Trial name
- NCT05575492
- Testing
- mRNA-1647
- Where
- 57 sites in United States, Canada and 1 more
- Volunteers
- 873 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Cytomegalovirus Infection
Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)
The purpose of this study was to evaluate the safety and efficacy of letermovir (LET) versus placebo when cytomegalovirus (CMV) prophylaxis was extended from 100 days to 200 days post-transplant in CMV seropositive participants…
- Trial name
- NCT03930615
- Testing
- Letermovir
- Where
- 32 sites in United States, France and 4 more
- Volunteers
- 220 people
- Sponsor
- Merck Sharp & Dohme LLC
Cytomegalovirus, Kidney Transplantation
Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Kidney Transplant Recipients
This study aims to validate whether Lophius Biosciences Kit T-Track® CMV is suitable to assess the functionality of CMV-specific cell-mediated immunity (CMI) and to determine a protective cut-off value for CMV…
- Conditions
- Cytomegalovirus, Kidney Transplantation, CMV Specific Immune Response
- Trial name
- CMValue (NCT02083042)
- Where
- Germany
- Volunteers
- 97 people
- Sponsor
- Lophius Biosciences GmbH
Cytomegalovirus Retinitis, HIV Infections
A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS
The purpose of this study is to see if valganciclovir is a safe treatment for CMV retinitis in patients who have been treated for this condition in the past.
- Trial name
- NCT00002222
- Testing
- Valganciclovir
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Hoffmann-La Roche
Healthy Adult Subjects
Safety and Pharmacokinetics of Single Oral Doses of MBX-400 in Healthy Volunteers
The purpose of this study is to determine the safety and pharmacokinetics following a single oral dose of MBX-400.
- Trial name
- NCT01433835
- Testing
- MBX-400
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Microbiotix, Inc.
Cytomegalovirus Infections
A Study of Human Cytomegalovirus (HCMV) Vaccine SPYVLP01 With and Without Adjuvants
The main purpose of the study is to evaluate the safety and immunogenicity of SPYVLP01 in two different doses with and without adjuvants in healthy adults aged 18-50 years old.
- Trial name
- SPYVAC01 (NCT06145178)
- Testing
- SPYVAC01
- Where
- 2 sites in United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- SpyBiotech Limited
Cytomegalovirus Retinitis, HIV Infections
A Randomized Study Comparing the Safety and Efficacy of Two Regimens of Oral Ganciclovir to Intravenous Ganciclovir Maintenance Therapy for Cytomegalovirus Retinitis in People With AIDS Who Have Received Prior Ganciclovir Therapy
To compare the safety and tolerance of oral ganciclovir at a double dose 3 times/day or a single dose 6 times/day to IV ganciclovir given for 20 weeks of maintenance therapy.
- Trial name
- NCT00002247
- Testing
- Ganciclovir
- Where
- 20 sites in United States, Canada
- Volunteers
- 225 people
- Sponsor
- Hoffmann-La Roche
HCMV
Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients
This study is designed to test if CSJ148 can prevent HCMV replication after stem cell transplantation.
- Trial name
- NCT02268526
- Testing
- CSJ148
- Where
- 17 sites in United States, Belgium and 4 more
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Cytomegalovirus Infection
Maribavir for Prevention of CMV After Stem Cell Transplants
Cytomegalovirus (CMV) infections remain a significant problem following various types of transplants that are associated with strong immunosuppressive therapy.
- Trial name
- NCT00223925
- Testing
- Maribavir
- Where
- 13 sites in United States
- Volunteers
- 111 people
- Sponsor
- Shire